Accessibility Statement Skip Navigation
  • Resources
  • Data Privacy
  • Contact Us
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • All Multimedia

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Accessories
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High-Tech Security
        • Internet Technology
        • Nanotechnology
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Projections or Forecasts
        • Financing Agreements
        • Insurance
        • Joint Ventures
        • Mutual Funds
        • Offerings
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing/marketing agreements
        • New Products & Services
        • Obituary
        • Outsourcing Businesses
        • Overseas Real Estate (Non-US)
        • Personnel Announcements
        • Residential Real Estate
        • Small-Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Accessories
        • Computer Electronics
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Design Automation
        • Financial Technology
        • Mobile Devices/Apps
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Natural Gas Utilities
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Computer Accessories
        • Computer Networks
        • Mobile Devices/Apps
        • Telecommunications
        • Telecommunications Carriers & Services
        • Telecommunications Equipment
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wine & Spirits
        • Beverages
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infectious Disease Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental Products & Services
        • European Government
        • Natural Disasters
        • Not-for-Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Children-related news
        • Disabled Persons
        • Diversity, Equity & Inclusion
        • Hispanic-oriented news
        • LGBTQ+
        • Religion
        • Senior Citizens
        • Veterans
        • Women-Related news
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Request a Demo
    • Partnerships
    • Media Inquiries
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring Home
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us


    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • News Releases
      • Send a Release
      • Data Privacy
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • News Releases
      • Send a Release
      • Data Privacy
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • News Releases
      • Send a Release
      • Data Privacy
      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries
      • Editorial Bureaus
      • News Releases
      • Send a Release
      • Data Privacy
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • All Multimedia
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Prenetics Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year's End


      News provided by

      Prenetics

      12 Sep, 2025, 22:50 CST

      Share this article

      Share this article


      1st Half revenue grew 452.1% to $32.3 million YoY

      IM8 achieved $5.9 million revenue in August 2025, representing a CAGR[1] of over 3,100%

      Prenetics increases FY2025 revenue guidance range of $85 – $100 million

      Prenetics provides update on Bitcoin Treasury, adding a total of 228 Bitcoin, and accumulating 1 BTC daily

      Prenetics to achieve break-even in Q1 2026, and EBITDA positive moving forward

      HONG KONG, Sept. 12, 2025 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2025, along with recent business updates.

      Danny Yeung, Chief Executive Officer and Co-Founder remarked "This quarter marks a pivotal moment for Prenetics as we demonstrate the successful execution of our strategic vision. The phenomenal growth of IM8, which is on track to achieve an unprecedented $100 million in annual recurring revenue within just our first year of operations, represents a milestone that is virtually unheard of in any industry. With IM8 currently generating $5.9 million in monthly revenue in August, we aim to hit $9 million per month by the end of the year, which would solidify our path to this extraordinary achievement. With such strong growth momentum, we believe we can build IM8 into one of the World's largest health and wellness brands in the coming years. Beyond the financial metrics, what makes me truly proud is the positive impact IM8 has had on so many people's health and wellness journeys - with over 8 million servings delivered and more than 300,000 customer orders, we are genuinely making a difference in people's lives."

      Danny further added "We've embraced a new strategic philosophy focused on optimizing both health and wealth - just as IM8 enhances people's physical well-being, our disciplined Bitcoin treasury strategy is designed to enhance our financial well-being and create long-term value preservation for our shareholders. We are not just building a successful health sciences company; we are building a company that is forward-thinking and resilient. With a strong balance sheet of $90 million in cash and BTC, a clear path to profitability in early 2026, and multiple avenues for growth, we are more confident than ever in our ability to deliver significant and sustainable long-term value to our shareholders."

      Second Quarter 2025 Financial Highlights[2]

      • Revenue of $17.7 million in the second quarter of 2025, an increase of 594.9% as compared to the second quarter of 2024.
      • Gross profit of $7.3 million in the second quarter of 2025, an increase of 233.5% as compared to the second quarter of 2024.
      • Adjusted EBITDA[3] loss of $(4.1) million in the second quarter of 2025, a decrease of 8.7% as compared to the first quarter of 2025.
      • Loss of $(10.9) million in the second quarter of 2025, an increase of 22.7% as compared to the second quarter of 2024.
      • Adjusted current assets[4] were $90.3 million, including $63.5 million of cash. As of September 10, 2025, the Company held 228.42 Bitcoin[5] with a value of $26.1 million and remained debt-free.

      [1] CAGR refers to the annualized rate derived by applying the standard CAGR formula to IM8's eight-month revenue increase from December 2024 to August 2025.

      [2] Unless otherwise specified, financial figures in this press release denotes results from continuing operations, which excludes our divested ACT Genomics. Refer to section ACT Genomics Divestment on the divestment of ACT Genomics and related IFRS Accounting Standards.

      [3] Adjusted EBITDA is a non-IFRS financial measure defined as loss for the period excluding (1) depreciation and amortization, (2) interest income, (3) other finance costs, (4) income tax (credit)/expense, (5) amortization of deferred expenses, (6) equity-settled share-based payment expenses, (7) acquisition and transaction-related costs, (8) strategic realignment and discontinued products impact, (9) exchange gain or loss, net, (10) fair value loss on financial assets at fair value through profit or loss, (11) fair value loss on warrant liabilities, (12) share of loss of equity-accounted investees, net of tax, and (13) loss from discontinued operation, net of tax. These adjustments are made for items that may not be indicative of our business performance, including non-cash and/or non-recurring items.

      [4] Represents current assets, including estimated proceeds from the divestment of ACT Genomics in the form of $46.3 million to be settled in cash, cash and cash equivalents totaling $17.2 million, financial assets at fair value through profit or loss of $10.5 million, and trade receivables of $1.8 million, amongst other accounting line items under current assets as of June 30, 2025.

      [5] Bitcoin is classified as non-current intangible assets under IFRS Accounting Standards. Bitcoin holdings value is as of September 10, 2025.

      Second Quarter Business Unit Revenue Breakdown:

      • IM8 - $9.8 million (Increase of 70% over Q1)
      • Europa - $5.7 million
      • CircleDNA - $2.2 million

      First Half 2025 Financial Highlights

      • Revenue of $32.3 million in the first half 2025, an increase of 452.1% as compared to the first half 2024.
      • Gross profit of $13.2 million in the first half 2025, expanded by 166.4% as compared to the first half 2024.
      • Adjusted EBITDA loss of $(8.7) million in the first half 2025, an increase of 45.4% as compared to the first half 2024.
      • Loss of $(19.8) million in the first half 2025, an increase of 30.2% as compared to the first half 2024.

      First Half Business Unit Revenue Breakdown:

      • IM8 - $15.5 million
      • Europa - $12.0 million
      • CircleDNA - $4.8 million

      Business Updates and Strategic Initiatives

      IM8 Strong Business Momentum:

      IM8 Health, a brand 100% wholly owned by Prenetics, has rapidly emerged as one of the fastest-growing supplement brands globally since its launch in December 2024. The brand's high-profile status with David Beckham as its co-founding partner is further bolstered by its multi-year partnership with Aryna Sabalenka, the World No. 1 tennis player and 2025 US Open champion, who serves as a global ambassador and Prenetics shareholder. The brand's marketing prowess was demonstrated during the US Open with an AI-powered Aryna Sabalenka video that went viral on Instagram, generating an extraordinary 233 million views. The campaign also featured prominently on the iconic Times Square billboard throughout the US Open and will continue running through the end of September, showcasing IM8's ability to capture global attention and drive brand awareness at scale.

      IM8 has further strengthened its scientific advisory board with the addition of Dr. Darshan Shah, a leading regenerative medicine physician and longevity expert; Dr. Ara Suppiah, a renowned sports medicine specialist and performance optimization physician; and Simon Hill, a prominent nutritionist and plant-based nutrition advocate. Looking ahead, the company is very excited about its new upcoming products, which will be best-in-class from a science perspective, further strengthening IM8's position as a leader in premium nutrition and longevity solutions.

      IM8 has demonstrated exceptional growth, with monthly net revenue surging from $581,000 in December 2024 to $5.9 million in August 2025, representing a compound annual growth rate (CAGR)[1] of over 3,100%. This remarkable performance is underscored by strong underlying business fundamentals and a highly efficient customer acquisition strategy. In the first half of 2025, IM8 Health achieved a 80%+ new customer subscription rate and an average order value of $110, reflecting strong customer loyalty and high-value transactions. With a gross margin of 52% and a customer acquisition cost of $104 in the first half of 2025, the brand's unit economics are compelling, further evidenced by an implied LTV/CAC ratio of 4.8x. To date, IM8 has processed more than 300,000 customer orders and delivered more than 8 million servings of its flagship product, IM8 Daily Ultimate Essentials, solidifying its position as a significant player in the crowded health and wellness market.

      IM8 Health - Key Performance Indicators (1H 2025 unless otherwise indicated)

      Metric

      Value

      August 2025 Revenue

      $5.9 million

      CAGR

      3,100 %

      New Customer Subscription Rate

      80 %

      Average Order Value

      $110.00

      Gross Margin

      52 %

      Customer Acquisition Cost (CAC)

      $104.00

      Projected 12-Month Lifetime Value (LTV)

      ~$500

      Implied LTV/CAC Ratio

      4.8x

      Total Customer Orders

      148,261

      Total Customer Orders (up to September 11, 2025)

      300,000+

      Total Servings Served (up to September 11, 2025)

      8 million+

      Strategic Bitcoin Treasury Initiatives:

      Leveraging our strong cash position and robust business fundamentals, we initiated a disciplined treasury reserve program in the second quarter, starting with an initial $20 million purchase of 187.42 BTC at an average price of $106,712 BTC in June 2025. This was followed by our programmatic daily accumulation of Bitcoin as a primary treasury reserve asset, funded directly from our operating cash beginning on August 1, 2025. As of September 10, 2025, the company holds 228.42 BTC on its balance sheet, acquired at an overall average price of approximately $108,131 per BTC. At the current Bitcoin price of $115,105, this position reflects an unrealized gain of approximately $1.6 million, equating to an annualized yield of roughly 30% since the initiation of our program in June 2025.

      Looking ahead, we plan to continue our disciplined approach with daily acquisitions of 1 BTC through the remainder of 20256, with expectations to further increase our accumulation rate in 2026 as our cash generation continues to strengthen. Additional purchase will be funded from available cash flows while maintaining prudent operating liquidity. This strategic move reflects our conviction in Bitcoin as a superior store of value and a compelling, non-correlated asset with significant long-term appreciation potential. By systematically converting a portion of our cash flows into Bitcoin, we are not only preserving our capital against inflationary pressures but also positioning Prenetics to capture the asymmetric upside of this emerging asset class. We believe this proactive and forward-thinking treasury management approach will enhance our financial strength and create substantial long-term value for our shareholders.

      To further enhance transparency, we have launched a dedicated Bitcoin Treasury Analytics page, which provides real-time updates on our holdings and performance, available at: https://www.prenetics.com/btc 

      Business Outlook

      Prenetics increases full-year 2025 guidance range of $85 - 100 million in revenue and expects to achieve breakeven by Q1 2026. Our combination of disciplined execution in consumer health, strengthening brand equity at IM8, a flexible capital markets posture, and strong balance sheet positions Prenetics to deliver significant growth.

      Breakdown of Full-Year Business Unit Revenue Guidance:

      • IM8: $55 - $60 million
      • Europa: $20 - $25 million
      • CircleDNA: $10 - $15 million

      ACT Genomics Divestment

      We announced on June 18, 2025 on the divestment of ACT Genomics to Delta Electronics, Inc for a total transaction value of approximately $71.8 million, with a gross proceeds to Prenetics of $46.3 million as settlement. Closing is progressing as planned and is expected in Q4 2025. In line with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations, ACT Genomics has been classified as a disposal group held for sale and a discontinued operation. Accordingly, its results are presented separately from continuing operations, and prior-period comparatives have been re-presented for consistency.

      About Prenetics

      Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer health. Our consumer initiative is led by IM8, one of the World's fastest growing supplement brands, Europa, one of the largest sports distribution companies in the USA, and CircleDNA, a leading direct-to-consumer DNA test. As the first consumer healthcare company to establish a Bitcoin treasury with its initial $20 million Bitcoin purchase and board-approved comprehensive Bitcoin strategy, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption. To learn more please visit www.prenetics.com and www.IM8health.com. 

      About IM8

      IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature's most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8's flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com. 

      Forward-Looking Statements

      This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance (including revenue ranges and breakdown timing) reflects management's current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to," "guidance," "outlook," "forecast," or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company's ability to further develop and grow its business, including new products and services; its ability to execute on its new business strategy in genomics, precision oncology, and specifically, early detection for cancer; the results of case control studies and/or clinical trials; and its ability to identify and execute on M&A opportunities, especially in precision oncology. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the "Risk Factors" section of the Company's most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

      Basis of Presentation

      Prior year/ period figures have been re-presented in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations, as result of the ACT Genomics divestment, the Group has classified ACT Genomics as held for sale and discontinued operations in June 2025.

      Unaudited Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release. An explanation of these measures is also included below under the heading "Unaudited Non-IFRS Financial Measures".

      Unaudited Non-IFRS Financial Measures

      To supplement Prenetics' consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), the Company is providing non-IFRS measure, adjusted EBITDA loss from continuing operations. This non-IFRS financial measure is not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes this non-IFRS financial measure is useful to investors in evaluating the Company's ongoing operating results and trends.

      Management is excluding from some or all of its non-IFRS results (1) depreciation and amortization, (2) interest income, (3) other finance costs, (4) income tax (credit)/expense, (5) amortization of deferred expenses, (6) equity-settled share-based payment expenses, (7) acquisition and transaction-related costs, (8) strategic realignment and discontinued products impact, (9) exchange gain or loss, net, (10) fair value loss on financial assets at fair value through profit or loss, (11) fair value loss on warrant liabilities, (12) share of loss of equity-accounted investees, net of tax, and (13) loss from discontinued operation, net of tax — items that may not be indicative of our business, results of operations, or outlook, including but not limited to non-cash and/ or non-recurring items. These non-IFRS financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on an IFRS basis as well as a non-IFRS basis and also by providing IFRS measures in the Company's public disclosures.

      In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company's non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the non-IFRS reconciliations provided in the tables captioned "Reconciliation of loss for the period under IFRS and adjusted EBITDA loss (Non-IFRS)", "Revenue by business unit from continuing operations (Non-IFRS)" and "Reconciliation of current assets under IFRS and adjusted current assets (Non-IFRS)" set forth at the end of this document.

      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of financial position

      (All amounts in thousands of U.S. dollars ("$"))



      June 30,


      March 31,


      December 31,


      2025


      2025


      2024




      (Restated)


      (Restated)

      Assets






      Property, plant and equipment

      $                    2,744


      $                    3,256


      $                    3,780

      Intangible assets

      273


      380


      488

      Cryptocurrency assets

      20,285


      —


      —

      Goodwill

      8,194


      8,194


      8,194

      Interests in equity-accounted investees

      66,693


      67,038


      67,396

      Financial assets at fair value through profit or loss

      1,103


      1,103


      1,103

      Other non-current assets

      449


      451


      451

      Non-current assets

      99,741


      80,422


      81,412

      Deferred expenses

      —


      1,492


      3,549

      Inventories

      4,297


      4,629


      4,736

      Trade receivables

      1,845


      1,669


      1,372

      Deposits, prepayments and other receivables

      8,151


      6,280


      7,488

      Amount due from a disposal group

      2,012


      2,181


      2,630

      Amount due from a related company

      21


      3


      3

      Financial assets at fair value through profit or loss

      10,462


      10,562


      10,562

      Cash and cash equivalents

      17,249


      43,153


      45,406

      Current assets

      44,037


      69,969


      75,746

      Assets classified as held for sale

      55,328


      55,806


      59,044

      Total assets

      $                199,106


      $                206,197


      $                216,202

      Liabilities






      Deferred tax liabilities

      $                           5


      $                         44


      $                         25

      Warrant liabilities

      875


      237


      175

      Lease liabilities

      1,048


      1,381


      1,760

      Other non-current liabilities

      228


      229


      230

      Non-current liabilities

      2,156


      1,891


      2,190

      Trade payables

      4,958


      3,364


      2,007

      Accrued expenses and other current liabilities

      8,692


      8,173


      7,099

      Contract liabilities

      6,623


      6,169


      6,475

      Lease liabilities

      1,526


      1,619


      1,691

      Tax payable

      13


      13


      13

      Current liabilities

      21,812


      19,338


      17,285

      Liabilities associated with assets classified as held for sale

      24,246


      23,870


      25,370

      Total liabilities

      48,214


      45,099


      44,845

      Equity






      Share capital

      20


      20


      19

      Reserves

      119,880


      129,232


      137,754

      Amounts recognized in other comprehensive income and accumulated
         in equity relating to assets classified as held for sale

      31,082


      31,936


      33,673

      Total equity attributable to equity shareholders of the Company

      150,982


      161,188


      171,446

      Non-controlling interests

      (90)


      (90)


      (89)

      Total equity

      150,892


      161,098


      171,357

      Total equity and liabilities

      $                199,106


      $                206,197


      $                216,202

      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of profit or loss and other comprehensive income

      (All amounts in thousands of U.S. dollars ("$") unless otherwise indicated)



      Six Months Ended


      June 30,


      June 30,


      2025


      2024




      (Restated)

      Continuing operations




      Revenue

      $                  32,276


      $                    5,846

      Direct costs

      (19,099)


      (899)

      Gross profit

      13,177


      4,947

      Other income and other net gain

      8


      1,101

      Selling and distribution expenses6

      (9,590)


      (2,750)

      Research and development expenses6

      (3,219)


      (4,801)

      Administrative and other operating expenses6

      (18,803)


      (12,969)

      Loss from operations

      (18,427)


      (14,472)

      Fair value loss on financial assets at fair value through profit or loss

      (100)


      (141)

      Fair value loss on warrant liabilities

      (700)


      (87)

      Share of loss of equity-accounted investees

      (409)


      (671)

      Other finance costs

      (141)


      (19)

      Loss before taxation

      (19,777)


      (15,390)

      Income tax credit

      13


      208

      Loss from continuing operations

      (19,764)


      (15,182)

      Discontinued operation




      Loss from discontinued operation, net of tax7

      (3,979)


      (5,015)

      Loss for the period

      (23,743)


      (20,197)

      Other comprehensive (expense)/income for the period




      Items that will not be reclassified subsequently to profit or loss:




      Share of other comprehensive income of equity-accounted investees

      (294)


      —

      Gain on revaluation of intangible assets

      285


      —

      Item that may be reclassified subsequently to profit or loss:




      Exchange difference on translation of foreign operations

      397


      (771)

      Total comprehensive expense for the period

      $                (23,355)


      $                (20,968)

      Loss attributable to:




      Equity shareholders of Prenetics

      $                (22,800)


      $                (19,290)

      Non-controlling interests

      (943)


      (907)


      $                (23,743)


      $                (20,197)

      Total comprehensive expense attributable to:




      Equity shareholders of Prenetics

      $                (22,423)


      $                (19,926)

      Non-controlling interests

      (932)


      (1,042)


      $                (23,355)


      $                (20,968)

      Loss per share:




      Basic

      (1.74)


      (1.58)

      Diluted

      (1.74)


      (1.58)

      Loss per share - Continuing operations:




      Basic

      (1.51)


      (1.24)

      Diluted

      (1.51)


      (1.24)

      Weighted average number of common shares:




      Basic

      13,126,271


      12,219,121

      Diluted

      13,126,271


      12,219,121

      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of profit or loss and other comprehensive income

      (All amounts in thousands of U.S. dollars ("$") unless otherwise indicated)



      Three Months Ended


      June 30,


      March 31,


      June 30,


      2025


      2025


      2024




      (Restated)


      (Restated)

      Continuing operations






      Revenue

      $                  17,680


      $                  14,596


      $                    2,544

      Direct costs

      (10,391)


      (8,708)


      (358)

      Gross profit

      7,289


      5,888


      2,186

      Other income and other net gain

      (196)


      204


      448

      Selling and distribution expenses[6]

      (5,457)


      (4,133)


      (1,662)

      Research and development expenses[6]

      (1,212)


      (2,007)


      (2,498)

      Administrative and other operating expenses[6]

      (10,489)


      (8,314)


      (6,676)

      Loss from operations

      (10,065)


      (8,362)


      (8,202)

      Fair value loss on financial assets at fair value through profit or
         loss

      (100)


      —


      (141)

      Fair value loss on warrant liabilities

      (637)


      (63)


      (168)

      Share of loss of equity-accounted investees

      (87)


      (322)


      (377)

      Other finance costs

      (65)


      (76)


      (15)

      Loss before taxation

      (10,954)


      (8,823)


      (8,903)

      Income tax credit/(expense)

      33


      (20)


      5

      Loss from continuing operations

      (10,921)


      (8,843)


      (8,898)

      Discontinued operation






      Loss from discontinued operation, net of tax[7]

      (1,806)


      (2,173)


      (2,248)

      Loss for the period

      (12,727)


      (11,016)


      (11,146)

      Other comprehensive (expense)/income for the period






      Items that will not be reclassified subsequently to profit or loss:






      Share of other comprehensive income of equity-accounted
         investees

      (258)


      (36)


      —

      Gain on revaluation of intangible assets

      285


      —


      —

      Item that may be reclassified subsequently to profit or loss:






      Exchange difference on translation of foreign operations

      294


      103


      (340)

      Total comprehensive expense for the period

      $                (12,406)


      $                (10,949)


      $                (11,486)

      Loss attributable to:






      Equity shareholders of Prenetics

      $                (12,410)


      $                (10,390)


      $                (10,722)

      Non-controlling interests

      (317)


      (626)


      (424)


      $                (12,727)


      $                (11,016)


      $                (11,146)

      Total comprehensive expense attributable to:






      Equity shareholders of Prenetics

      $                (12,180)


      $                (10,243)


      $                (10,925)

      Non-controlling interests

      (226)


      (706)


      (561)


      $                (12,406)


      $                (10,949)


      $                (11,486)

      Loss per share:






      Basic

      $                    (0.94)


      $                    (0.80)


      $                    (0.88)

      Diluted

      (0.94)


      (0.80)


      (0.88)

      Loss per share - Continuing operations:






      Basic

      (0.82)


      (0.68)


      (0.73)

      Diluted

      (0.82)


      (0.68)


      (0.73)

      Weighted average number of common shares:






      Basic

      13,247,315


      13,003,881


      12,222,337

      Diluted

      13,247,315


      13,003,881


      12,222,337

      PRENETICS GLOBAL LIMITED

      Unaudited Non-IFRS Financial Measures

      (All amounts in thousands of U.S. dollars ("$"))


      Reconciliation of loss for the period under IFRS and adjusted EBITDA (Non-IFRS)



      Six Months Ended


      June 30,


      June 30,


      2025


      2024




      (Restated)

      Loss for the period under IFRS

      $                (23,743)


      $                (20,197)

      Depreciation and amortization

      1,248


      1,311

      Interest income

      (731)


      (1,047)

      Other finance costs

      141


      19

      Income tax credit

      (13)


      (208)

      EBITDA under IFRS

      (23,098)


      (20,122)

      Amortization of deferred expenses

      3,549


      4,133

      Equity-settled share-based payment expenses

      3,054


      3,319

      Acquisition and transaction-related costs

      1,799


      798

      Strategic realignment and discontinued products impact

      10


      37

      Exchange gain or loss, net

      841


      (34)

      Fair value loss on financial assets at fair value through
         profit or loss

      100


      141

      Fair value loss on warrant liabilities

      700


      87

      Share of loss of equity-accounted investees, net of tax

      409


      671

      Loss from discontinued operation, net of tax

      3,979


      5,015

      Adjusted EBITDA (Non-IFRS)

      $                  (8,657)


      $                  (5,955)


      Three Months Ended


      June 30,


      March 31,


      June 30,


      2025


      2025


      2024




      (Restated)


      (Restated)

      Loss for the period under IFRS

      $                (12,727)


      $                (11,016)


      $                (11,146)

      Depreciation and amortization

      617


      631


      517

      Interest income

      (309)


      (422)


      (522)

      Other finance costs

      65


      76


      15

      Income tax (credit)/expense

      (33)


      20


      (5)

      EBITDA under IFRS

      (12,387)


      (10,711)


      (11,141)

      Amortization of deferred expenses

      1,492


      2,057


      2,045

      Equity-settled share-based payment expenses

      1,887


      1,167


      1,464

      Acquisition and transaction-related costs

      1,674


      125


      798

      Strategic realignment and discontinued products impact

      8


      2


      29

      Exchange gain or loss, net

      564


      277


      82

      Fair value loss on financial assets at fair value through
         profit or loss

      100


      —


      141

      Fair value loss on warrant liabilities

      637


      63


      168

      Share of loss of equity-accounted investees, net of tax

      87


      322


      377

      Loss from discontinued operation, net of tax

      1,806


      2,173


      2,248

      Adjusted EBITDA (Non-IFRS)

      $                  (4,132)


      $                  (4,525)


      $                  (3,789)

      PRENETICS GLOBAL LIMITED

      Unaudited Non-IFRS Financial Measures

      (All amounts in thousands of U.S. dollars ("$"))


      Revenue by business unit from continuing operations (Non-IFRS)



      Six Months Ended


      June 30,


      June 30,


      2025


      2024




      (Restated)

      Continuing operations




      CircleDNA

      $                    4,752


      $                    5,846

      IM8

      15,486


      —

      Europa

      12,038


      —


      $                  32,276


      $                    5,846


      Three Months Ended


      June 30,


      March 31,


      June 30,


      2025


      2025


      2024




      (Restated)


      (Restated)

      Continuing operations






      CircleDNA

      $                    2,210


      $                    2,542


      $                    2,544

      IM8

      9,754


      5,732


      —

      Europa

      5,716


      6,322


      —


      $                  17,680


      $                  14,596


      $                    2,544

      Reconciliation of current assets under IFRS and adjusted current assets (Non-IFRS)


      June 30,


      December 31,


      2025


      2024




      (Restated)

      Current assets under IFRS

      $                  44,037


      $                  75,747

      Estimated cash proceeds from the divestment of ACT
         Genomics

      46,305


      —

      Adjusted current assets (Non-IFRS)

      $                  90,342


      $                  75,747

      —————————————————————————

      [6] Includes equity-settled share-based payment expenses from continuing operations as follows:


      Six Months Ended


      June 30,


      June 30,


      2025


      2024




      (Restated)

      Continuing operations




      Selling and distribution expenses

      $                           2


      $                         —

      Research and development expenses

      578


      1,567

      Administrative and other operating expenses

      1,425


      1,706

      Total employee equity-settled share-based payment expenses

      $                    2,005


      $                    3,273


      Three Months Ended


      June 30,


      March 31,


      June 30,


      2025


      2025


      2024




      (Restated)


      (Restated)

      Continuing operations






      Selling and distribution expenses

      $                          1


      $                          1


      $                        —

      Research and development expenses

      111


      467


      810

      Administrative and other operating expenses

      968


      457


      629

      Total employee equity-settled share-based payment
         expenses

      $                    1,080


      $                       925


      $                    1,439

      [7] ACT Genomics Holdings Company Limited ("ACT Genomics") are classified as discontinued operations in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations ("IFRS 5"). In accordance with IFRS 5, the results of the discontinued operation have been presented separately from the continuing operations in the consolidated statements of profit or loss and other comprehensive income.

      SOURCE Prenetics

      Modal title

      Contact PR Newswire

      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Become a Publishing Partner
      • Careers
      • Accessibility Statement
      • APAC – Simplified Chinese
      • APAC
      • APAC - Traditional Chinese
      • Arabic
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States
      • Vietnam

      My Services

      • All New Releases
      • Platform

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      [email protected]
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      • Accessibility
      Copyright © 2026 Cision US Inc.